Clinical development of voxtalisib: a pan-PI3K/mTOR inhibitor
Mené sur 167 patients atteints d'une leucémie lymphoïde chronique, d'un lymphome à petits lymphocytes ou d'un lymphome non hodgkinien récidivant ou réfractaire, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse globale, et la toxicité du voxtalisib, un inhibiteur des voies PI3K et mTOR
The B-cell receptor (BCR) signalling pathway has a key role in the survival of normal B lymphocytes, and signalling through the BCR is mediated in part by activation of PI3K. Constitutive activation of the PI3K/AKT/mTOR pathway by the BCR signalling pathway is regarded as one of the main contributors to pathogenesis in B-cell malignancies including B-cell non-Hodgkin lymphoma, chronic lymphocytic leukaemia, or small lymphocytic lymphoma. PI3K and mTOR have been considered attractive targeting molecules for the treatment of various B-cell malignancies as well as Bruton's tyrosine kinase.
The Lancet Haematology , commentaire, 2017